U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Grand Rounds
  1. About Science & Research at FDA

FDA Grand Rounds

FDA Grand Rounds

The FDA Grand Rounds is an educational presentation that is webcast monthly to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute educational presentation is followed by questions from the audience. You can also view the presentation under Past Grand Rounds following the live webcast. #FDAGrandRounds.

Upcoming Event

FDA Grand Rounds: Whole Genome Sequencing: A Powerful Scientific Tool that Delivered During the 2023 Pseudomonas Outbreak in Eye Drops

Thursday, May 9, 2024
12:00 p.m. - 1:00 p.m. ET

About the Speaker

Michelle Cockrell, B.S.
Office of Regulatory Affairs
Irvine Medical Products Laboratory
U.S. Food and Drug Administration

Michelle Cockrell received her undergraduate degree in Microbiology from the University of Oklahoma in 2017. She worked as a clinical microbiologist and molecular biologist for the Oklahoma State Department of Health where she developed an interest in whole genome sequencing and its significance as a tool for public health. In 2021, she moved to Irvine, California to start her career with the Food and Drug Administration. Now, she works as a microbiologist and lead for the whole genome sequencing workgroup for the Irvine Medical Products Laboratory.

Past Grand Rounds










Resources For You

Sub-Topic Paragraphs

Latest From the Commissioner

FDA Statement from Todd Simpson, FDA Chief Information Officer (CIO) on GAO Report Regarding FDA’s IT Security Program

Sep 29

Statement by FDA Commissioner Scott Gottlieb, M.D. on new steps by FDA to advance patient engagement in the agency’s regulatory work

Feb 28

Statement from FDA Commissioner Scott Gottlieb, M.D., on advancing new digital health policies to encourage innovation, bring efficiency and modernization to regulation

Dec 07

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance medical product communications to support drug competition and value-based health care

Jun 12

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s continued efforts relating to compounded drugs for patients who cannot use an FDA-approved drug

Jun 28

Statement from FDA Commissioner Scott Gottlieb, M.D., and Center for Devices and Radiological Health Director Jeff Shuren, M.D., J.D., on agency efforts to work with tech industry to spur innovation in digital health

Sep 12

Statement from Binita Ashar, M.D., of the FDA’s Center for Devices and Radiological Health on agency’s commitment to studying breast implant safety

Sep 14

Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s new effort for developing and class labeling of in vitro companion diagnostics for classes of oncology therapeutic products

Dec 06

Back to Top